About PT-141 (Bremelanotide)
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist indicated for hypoactive sexual desire disorder in premenopausal women (Vyleesi). It acts on MC3 and MC4 receptors in the central nervous system to modulate sexual arousal. It is distinct from PDE5 inhibitors in its mechanism of action.
PT-141 (Bremelanotide) & Sexual Health
PT-141 (Bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. RECONNECT trials demonstrated statistically significant improvement in sexual desire. It acts on MC3 and MC4 receptors in the CNS.
Content sourced from existing TruthTides clinical reference documentation. This is informational only. Consult a qualified physician.
Find a PT-141 (Bremelanotide) prescriber in San Antonio
Browse qualified physicians who prescribe PT-141 (Bremelanotide) in the San Antonio area, or search nationwide via telehealth.
Ask TruthSource AI
Ask anything about PT-141 (Bremelanotide) for Sexual Health
Get a guardrailed, evidence-anchored answer from our clinical reference tool.
Open Reference ToolFind a Doctor
Search verified PT-141 (Bremelanotide) prescribers nationwide
Filter by peptide, location, and telehealth availability.
Open Physician FinderPT-141 (Bremelanotide) for Sexual Health in Other Cities
This content is sourced from existing TruthTides clinical reference documentation. It does not constitute medical advice or treatment recommendations. Consult a qualified physician before starting any peptide therapy.